Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trialResearch in context

Summary: Background: BRAF V600 mutations are common in melanoma, thyroid, and non-small-cell lung cancers. Despite dabrafenib and trametinib being standard treatments for certain cancers, their efficacy across various solid tumours remains unelucidated. The BELIEVE trial assessed the efficacy of da...

Cijeli opis

Bibliografski detalji

Glavni autori:	Tatsunori Shimoi, Kuniko Sunami, Makoto Tahara, Satoshi Nishiwaki, Shota Tanaka, Eishi Baba, Masashi Kanai, Ichiro Kinoshita, Hidekazu Shirota, Hideyuki Hayashi, Naohiro Nishida, Toshio Kubo, Nobuaki Mamesaya, Yayoi Ando, Natsuko Okita, Taro Shibata, Kenichi Nakamura, Noboru Yamamoto
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2024-03-01
Serija:	EClinicalMedicine
Teme:	Bayesian statistics Platform clinical trials BRAF inhibitors MEK inhibitors Rare cancers
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2589537024000269
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!